Bönisch N, Langan E A, Terheyden P
Klinik für Dermatologie, Universität zu Lübeck, Lübeck, Deutschland.
Dermatological Science, University of Manchester, Manchester, Großbritannien.
Hautarzt. 2019 Sep;70(9):700-706. doi: 10.1007/s00105-019-4462-0.
Whilst cutaneous angiosarcoma is rare tumour which primarily affects elderly patients, its management presents a significant therapeutic challenge. Indeed, complete surgical excision is often not possible due to the location and the diffuse and extensive nature of the tumour. Therefore, current treatment strategies often include chemo- and/or radiotherapy.
We report our experience of combined chemo- and radiotherapy in the clinical course of 6 patients with cutaneous angiosarcoma who were treated between 2007 and 2018.
All patients presented non-resectable tumours and were treated with radiotherapy in combination with the administration of liposomal, pegylated doxrubicin (25 mg/m every 2 weeks). The mean duration of progression-free survival was 8 months (5-14 months), corresponding to an overall survival of 13 months (13-34 months). A partial response was seen in 4 patients and 1 patient developed progressive disease. One patient abandoned therapy after one administration. Two patients developed severe adverse events which led to termination of therapy after 1.5 months and 7 months, i.e. after 4 and 15 cycles respectively.
Combined radio- and chemotherapy with liposomal, pegylated doxorubicin is a useful therapeutic option in the management of cutaneous angiosarcoma. Given the short-lived response rate, new treatment options are urgently required.
皮肤血管肉瘤是一种罕见肿瘤，主要影响老年患者，其治疗面临重大挑战。实际上，由于肿瘤的位置以及弥漫性和广泛性，往往无法进行完整的手术切除。因此，目前的治疗策略通常包括化疗和/或放疗。
我们报告了2007年至2018年间接受治疗的6例皮肤血管肉瘤患者在联合化疗和放疗临床过程中的经验。
所有患者均表现为不可切除的肿瘤，并接受了放疗联合脂质体聚乙二醇化阿霉素（每2周25mg/m）治疗。无进展生存期的平均持续时间为8个月（5 - 14个月），总生存期为13个月（13 - 34个月）。4例患者出现部分缓解，1例患者疾病进展。1例患者在一次给药后放弃治疗。2例患者出现严重不良事件，分别在1.5个月和7个月（即4个周期和15个周期后）导致治疗终止。
脂质体聚乙二醇化阿霉素联合放疗和化疗是皮肤血管肉瘤治疗中的一种有用的治疗选择。鉴于缓解率持续时间短，迫切需要新的治疗选择。
